We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
Read MoreHide Full Article
Ecolab Inc. (ECL - Free Report) has been gaining from its focus on research and development (R&D). The optimism, led by a solid first-quarter 2024 performance, along with its solid product portfolio, is expected to contribute further. However, concerns arising from cost fluctuations and the possibility of unsuccessful integration persist.
This Zacks Rank #2 (Buy) stock has gained 18.1% year to date against the industry’s 19.6% decline. The S&P 500 Composite has increased 11.7% during the same time frame.
The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $67.11 billion. It projects 14.3% growth over the next five years and expects to maintain a strong performance going forward. Ecolab’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 1.3%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Focus on R&D: Ecolab’s R&D program primarily covers the development and validation of the performance of new products, processes, techniques and equipment. This improves the efficiency of the existing products and service program content and evaluates the environmental compatibility of products and technical support.
Management believes that continued R&D activities are critical to maintaining its leadership position within the industry and should provide it with a competitive edge as it seeks additional business with new and existing customers.
Well-Positioned for Long-Term Growth:Ecolab’s consistent delivery of considerable earnings growth despite macro uncertainties continues to impress. Management remains optimistic regarding improvement in its ability to attract new customers and opportunities for greater customer penetration through new product development.
Ecolab also makes business acquisitions that align with its strategic business objectives. In May 2023, the company acquired Chemlink Laboratories LLC, a U.S.-based producer of small-format cleaning solutions. Ecolab also made two other acquisitions during the second quarter of 2023. All three acquisitions have become accretive to the Global Institutional & Specialty segment and are likely to boost growth going forward.
Strong Q1 Results: Ecolab’s solid first-quarter 2024 results buoy optimism. Per management, Ecolab witnessed a strong first quarter with significant growth in organic sales and expansion in organic income margin. During the same time, the company drove pricing, which was backed by strong customer value, and improved its underlying productivity by leveraging its digital capabilities. On the earnings call in April, management stated that volumes in the first quarter continued to improve, reflecting new business wins.
On the first-quarter earnings call, management confirmed that it has entered into a definitive agreement for the sale of its global surgical solutions business to Medline for $950 million in cash. The sale is expected to close in the second half of 2024, subject to regulatory clearances and other customary closing conditions. The company expects to record an associated pre-tax gain.
Downsides
Cost Fluctuations: The cost of the raw materials that Ecolab uses in its operations is subject to occasional fluctuations. The company has also experienced periods of rising raw material costs in the last few years. Ecolab's combined operating results could be considerably and negatively impacted by changes in the price of raw materials and the lack of suitable and reasonably priced raw materials.
Possibility of Unsuccessful Integration: Ecolab seeks to acquire complementary businesses as part of its long-term strategy. There is no assurance that it will find attractive acquisition candidates or succeed at effectively managing the integration of acquired businesses. If the underlying business performance of such acquired businesses deteriorates or Ecolab fails to successfully integrate new businesses into its existing ones, the company’s consolidated results of operations could be adversely affected.
Estimate Trend
Ecolab is witnessing a positive estimate revision trend for 2024. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 3.1% north to $6.59 per share.
The Zacks Consensus Estimate for the company’s second-quarter 2024 revenues is pegged at $4.04 billion, indicating a 4.8% improvement from the year-ago quarter’s reported number.
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. (ALGN - Free Report) , DaVita (DVA - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Align Technology, carrying a Zacks Rank of 2, reported first-quarter 2024 adjusted earnings per share (EPS) of $2.14, beating the Zacks Consensus Estimate by 8.1%. Revenues of $997.4 million outpaced the consensus mark by 2.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Align Technology has a long-term estimated growth rate of 6.9%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 5.9%.
DaVita, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%.
DaVita’s shares have gained 40.1% compared with the industry’s 24.1% rise in the past year.
Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, beating the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 7.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
Ecolab Inc. (ECL - Free Report) has been gaining from its focus on research and development (R&D). The optimism, led by a solid first-quarter 2024 performance, along with its solid product portfolio, is expected to contribute further. However, concerns arising from cost fluctuations and the possibility of unsuccessful integration persist.
This Zacks Rank #2 (Buy) stock has gained 18.1% year to date against the industry’s 19.6% decline. The S&P 500 Composite has increased 11.7% during the same time frame.
The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $67.11 billion. It projects 14.3% growth over the next five years and expects to maintain a strong performance going forward. Ecolab’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average surprise of 1.3%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Focus on R&D: Ecolab’s R&D program primarily covers the development and validation of the performance of new products, processes, techniques and equipment. This improves the efficiency of the existing products and service program content and evaluates the environmental compatibility of products and technical support.
Management believes that continued R&D activities are critical to maintaining its leadership position within the industry and should provide it with a competitive edge as it seeks additional business with new and existing customers.
Well-Positioned for Long-Term Growth:Ecolab’s consistent delivery of considerable earnings growth despite macro uncertainties continues to impress. Management remains optimistic regarding improvement in its ability to attract new customers and opportunities for greater customer penetration through new product development.
Ecolab also makes business acquisitions that align with its strategic business objectives. In May 2023, the company acquired Chemlink Laboratories LLC, a U.S.-based producer of small-format cleaning solutions. Ecolab also made two other acquisitions during the second quarter of 2023. All three acquisitions have become accretive to the Global Institutional & Specialty segment and are likely to boost growth going forward.
Strong Q1 Results: Ecolab’s solid first-quarter 2024 results buoy optimism. Per management, Ecolab witnessed a strong first quarter with significant growth in organic sales and expansion in organic income margin. During the same time, the company drove pricing, which was backed by strong customer value, and improved its underlying productivity by leveraging its digital capabilities. On the earnings call in April, management stated that volumes in the first quarter continued to improve, reflecting new business wins.
On the first-quarter earnings call, management confirmed that it has entered into a definitive agreement for the sale of its global surgical solutions business to Medline for $950 million in cash. The sale is expected to close in the second half of 2024, subject to regulatory clearances and other customary closing conditions. The company expects to record an associated pre-tax gain.
Downsides
Cost Fluctuations: The cost of the raw materials that Ecolab uses in its operations is subject to occasional fluctuations. The company has also experienced periods of rising raw material costs in the last few years. Ecolab's combined operating results could be considerably and negatively impacted by changes in the price of raw materials and the lack of suitable and reasonably priced raw materials.
Possibility of Unsuccessful Integration: Ecolab seeks to acquire complementary businesses as part of its long-term strategy. There is no assurance that it will find attractive acquisition candidates or succeed at effectively managing the integration of acquired businesses. If the underlying business performance of such acquired businesses deteriorates or Ecolab fails to successfully integrate new businesses into its existing ones, the company’s consolidated results of operations could be adversely affected.
Estimate Trend
Ecolab is witnessing a positive estimate revision trend for 2024. In the past 90 days, the Zacks Consensus Estimate for its earnings has moved 3.1% north to $6.59 per share.
The Zacks Consensus Estimate for the company’s second-quarter 2024 revenues is pegged at $4.04 billion, indicating a 4.8% improvement from the year-ago quarter’s reported number.
Ecolab Inc. Price
Ecolab Inc. price | Ecolab Inc. Quote
Other Key Picks
Some other top-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. (ALGN - Free Report) , DaVita (DVA - Free Report) and Boston Scientific Corporation (BSX - Free Report) .
Align Technology, carrying a Zacks Rank of 2, reported first-quarter 2024 adjusted earnings per share (EPS) of $2.14, beating the Zacks Consensus Estimate by 8.1%. Revenues of $997.4 million outpaced the consensus mark by 2.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Align Technology has a long-term estimated growth rate of 6.9%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 5.9%.
DaVita, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%.
DaVita’s shares have gained 40.1% compared with the industry’s 24.1% rise in the past year.
Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, beating the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 7.5%.